A Phase I/II Study of the Combination of Indoximod and Temozolomide for Adult Patients With Temozolomide-Refractory Primary Malignant Brain Tumors

Trial Profile

A Phase I/II Study of the Combination of Indoximod and Temozolomide for Adult Patients With Temozolomide-Refractory Primary Malignant Brain Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Nov 2016

At a glance

  • Drugs Indoximod (Primary) ; Temozolomide
  • Indications Glioblastoma; Glioma; Gliosarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors NewLink Genetics Corporation
  • Most Recent Events

    • 29 Apr 2016 Mid-trial update from this trial is expected in the second half of 2016, according to a NewLink Genetics Corporation media release.
    • 23 Nov 2015 According to NewLink Genetics media release, company has enrolled 40 patients out of planned 132 patients in the phase 2 portion of the study.
    • 23 Nov 2015 Results presented on November 20 at the 20th Annual Scientific Meeting of the Society for Neuro-Oncology, as per NewLink Genetics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top